Project Grant R44CA306545
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60607, USA
Similar Awards
- The National Cancer Institute awarded Tiburon Bio Inc. $305,488 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a sustained-release multidomain peptide hydrogel formulation combining an iNOS inhibitor (L-NIL) and a STING-agonist (CDN) for use with immune checkpoint inhibitor monoclonal antibodies in neoadjuvant immunotherapy for resectable oral cancers. The work aims to enhance immune priming to control residual disease following tumor resection and...
- The National Cancer Institute awarded Cytoagents Inc. $1,313,567 on September 22, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop and advance CTO1681, a pharmaceutical compound designed to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapy. CTO1681 is an orally available compound that reduces transcription of proinflammatory cytokines implicated in cytokine release syndrome, a severe systemic inflammatory response...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $709,145 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate senescence-modulating nanoparticles targeting P-selectin on senescent cells as a strategy to potentiate cancer immunotherapy in fibrotic tumors. The project addresses a barrier in cancer immunotherapy: many patients with solid tumors remain unresponsive to immune checkpoint blockade and CAR T cell...
- The National Cancer Institute awarded University of Massachusetts Medical School $1.06 million on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to engineer multi-targeted nanoparticle-based immunotherapy for pancreatic cancer. The funded work develops lipid-based nanoparticles (NPs) carrying RAS pathway inhibitors (trametinib, palbociclib, or RMC-7977) and STING/TLR4 innate immune agonists, designed to home specifically to tumor cells and dendritic cells within the...
- The National Cancer Institute awarded Sinopia Biosciences Inc. $399,873 on September 22, 2025, to develop a metabolomics-enabled artificial intelligence and machine learning platform for discovery of new treatments to enhance drug sensitivity in cancer under the Cancer Biology Research program (CFDA 93.396). Sinopia Biosciences and its partner Omix Technologies are developing algorithms and computational methods to characterize how baseline metabolic states of cancers affect their sensitivity to...
- The National Cancer Institute awarded Persistence Therapeutics, Inc., $629,370 under the Cancer Treatment Research program (CFDA 93.395) on September 22, 2025, to develop and prototype SynthNode, an implantable device designed to improve CAR T cell therapy manufacturing and efficacy. SynthNode is a dime-sized implantable device that mimics a synthetic lymph node to produce potent, antigen-specific cells with enhanced durability and tumor-elimination capacity. The project addresses...
- The National Cancer Institute awarded Gigamune Inc. $800,000 on September 15, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop a novel lentivector for enhanced in vivo delivery of T cell receptors for cell therapy targeting stage IV melanoma. The research project, titled "A Novel Lentivector for Enhanced In Vivo Delivery of T Cell Receptors for Cell Therapy for Stage IV Melanoma" and led by principal investigator David Scott Johnson, Ph.D., aims to create an...
- The National Cancer Institute awarded Vesicle Therapeutics Inc. $400,000 on September 16, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop a targeted antisense oligonucleotide therapy for head and neck squamous cell carcinoma. Vesicle Therapeutics is synthesizing and evaluating a thiomorpholino-based antisense oligonucleotide designed to selectively inhibit the oncogenic STAT3A isoform while preserving the tumor-suppressive STAT3B isoform. The Phase I project...
- The National Cancer Institute awarded the Regents of the University of Michigan $669,421 on July 20, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop innate-immune-activating nanoparticles for cancer treatment. The funded work applies bioengineering principles to design STING-activating nanoparticles that overcome limitations of current cyclic dinucleotide-based STING agonists, including poor intracellular uptake, rapid in vivo degradation, and restriction to...
- The National Cancer Institute awarded Daybreak Pharmaceuticals Inc. $303,345 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a first-in-class synthetic RNA-based therapy targeting the mutagenic translesion synthesis pathway to enhance chemotherapy efficacy in non-small cell lung cancer. The project delivers proof-of-concept evaluation of translesion synthesis inhibition using a nucleic acid construct encoding a dominant-negative REV1 C-terminal...